Combination Therapy For The Treatment Of Influenza
Compositions And Methods For Treating One Or More Symptoms Of Influenza, Preferably Influenza Due To Infection With Influenza A (H5n1) Are Provided. It Has Been Discovered That Administration Of A Combination Of A Neuraminidase Inhibitor With Two Immunomodulators Increases Survivability In Subjects 24, 48, Or Even 72 Hours Post Infection Compared To Administration Of The Neuraminidase Inhibitor Alone. A Preferred Neuraminidase Inhibitor Is Zanamivir. Preferred Immunomodulators Include, But Are Not Limited To Celecoxib And Mesalazine. Another Embodiment Provides A Method For Treating Influenza, Preferably, Influenza Due To Infection With Avian Influenza A (H5n1) By Administering To Subject Infected With The Influenza Virus, An Effective Amount Of A Neuraminidase Inhibitor To Inhibit Or Reduce Budding Of The Influenza Virus From Infected Cells Of The Subject, And An Effective Amount Of At Least Two Immunomodulators Effective To Reduce Or Inhibit One Or More Symptoms Of Inflammation In The Subject.
Patent Number: CN102036658A
Application Number: CN200980119926A
Inventor: YUAN, Guo-yong | ZHENG, Bo-jian
Priority Date: 23 May 2008
Priority Number: CN102036658A
Application Date: 7 May 2009
Publication Date: 27 Apr 2011
IPC Current: A61K0031155 | A61K0031196 | A61K0031415 | A61K0031606 | A61P003116
Assignee Applicant: The University of Hong Kong
Title: Combination therapy for the treatment of influenza
Usefulness: Combination therapy for the treatment of influenza
Summary: For treating symptoms of influenza such as influenza A (H5N1); for inhibiting or reducing budding of influenza virus from infected cells, and reducing at least one symptoms of inflammation of the subject (claimed).
Novelty: Pharmaceutical composition useful for treating influenza A, comprises neuraminidase inhibitor to inhibit budding of influenza virus from infected cells; and at least two immunomodulators effective to reduce symptoms of inflammation
生物醫學
醫藥成分
香港
